Category: Other
Objective: There is an urgent need for validated biofluid biomarkers in Parkinson’s disease (PD) drug development. Under the auspices of the Critical Path for Parkinson’s Consortium (CPP) in collaboration with Michael J Fox foundation, initial steps are taken to take inventory and create a user-friendly dashboard that catalogues biofluid biomarkers and samples across PD clinical trial cohorts.
Background: The development of biomarkers for early diagnosis and disease progression in PD is urgently needed as clinical assessment alone cannot sufficiently reflect target engagement. To facilitate the identification of candidate biomarkers, several large longitudinal PD cohorts have been established that collect cerebrospinal fluid (CSF), blood and saliva; however, the biomarkers sampled across these cohorts are not standardized. The goal of this PD Biomarker Inventory and Dashboard is to create a unified dashboard to query across PD cohorts as an initial step to accelerate the validation process for biomarkers.
Method: An initial inventory was constructed using PPMI PD cohort as a framework for variables and results to capture. Using this framework, data has been tabulated to provide an overview of each cohort including which biofluid samples were collected, how many PD patients were included in the cohort, and PD disease stage. On the resulting publications the biospecimens examined, biomarkers measured, inflammatory mediators measured, and key findings and conclusions from the study were also documented. The data was then collected to display into an interactive dashboard to make it searchable and user-friendly.
Results: Progress to date includes the development of an inventory of 16 PD cohorts. Among these cohorts, early stage PD patients were the most sampled, and whole blood and CSF were the most sampled. CSF, serum, and plasma were most reported on in publications, with alpha-synuclein the most prevalent biomarker. This data has all been categorized into an interactive searchable dashboard.
Conclusion: A biomarker inventory for PD is an important first step to evaluating the data and samples available across global PD cohorts. An open access user friendly interactive dashboard will make it simpler to find existing data on PD cohorts and research on PD biomarkers. Future strategies include expanding the inventory to include additional PD cohorts and neuroimaging biomarker data.
To cite this abstract in AMA style:
M. Pauley, K. Merchant, S. Hutten, M. Frasier, M. Lawton, D. Dexter, M. Muller, D. Stephenson. The Development of a Parkinson’s Disease Biomarker Inventory Dashboard [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/the-development-of-a-parkinsons-disease-biomarker-inventory-dashboard/. Accessed September 7, 2024.« Back to MDS Virtual Congress 2021
MDS Abstracts - https://www.mdsabstracts.org/abstract/the-development-of-a-parkinsons-disease-biomarker-inventory-dashboard/